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Dear Editor,
I read the article on “Seroprevalence study of hepatitis 
A virus in Fars province, southern Iran” that published in 
one of previous issues of Hepatitis Monthly by Taghavi 
SA et al. in which authors recommended hepatitis A vac-
cination in five year old children (1). In developed coun-
tries the first dose of hepatitis A vaccination injects in 
one year old children while some other researchers rec-
ommend second dose after 9-15 months. There are Two 
main methods to prevent hepatitis A infection: 1) pas-
sive immunoprophylaxis; 2) active immunoprophylaxis 
through vaccination (2). In developing countries that al-
most all adults carry HAV antibody, general vaccination 
isn’t cost benefit but due to reduction in HAV infection in 
children, it seems that vaccination may be requirement, 
on the other hand, prevalence of HAV differs in devel-
oped and developing countries, therefore, the best age 
for vaccination against HAV may be different. 
Iran is an endemic area for hepatitis A infection but the 
prevalence varies in different provinces (3). Recently, im-
provement on both environment sanitation and healthy 
water and food has decreased clinical HAV infection in 
childhood that is why this life threating infection seems 
more common among adults. Passive immunoprophy-
laxis also may be one other strategy of HAV prevention 
in mini epidemic or family outbreak in developing coun-
tries. In endemic area human serum immunoglobulin 
can be used in persons within two weeks after exposure 
(4). Immunoglobulin is as effective as vaccination and it 
should be used in countries that HAV vaccination is not 
available such as Iran, but it isn’t approved for general 
prevention. In developed countries children receive HAV 
vaccination at the  age of one; however, it may be differ-
ent in developing countries in which HAV and mother 
immunity transmitted is endemic and it causes neona-
tal immunity for long time (5). It seems that suggestion 
of vaccination in five year old children in the mentioned 
article needs to be evaluated more practically.
In conclusion, more studies on seroepidemology of 
hepatitis A virus are required to evaluate the most appro-
priate age of HAV vaccination among vhildren in devel-
oping countries.
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